Navigation Links
Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0286181/Women's-Infertility---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

SummaryGlobalData, the industry analysis specialist, has released its new report, "Women's Infertility - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global women's infertility therapeutics market. The report identifies the key trends shaping and driving the global women's infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global women's infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global women's infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015

ScopeThe Scope of the report includes:

- Annualized global women's infertility therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Gonadotropin-Releasing hormone (GnRH) antagonists, AMP-activated protein kinase (AMPK) agonists, GnRH agonists, Recombinant human chorionic gonatropin, Follicle stimulating hormone, Selective Estrogen Receptor Modulators (SERMs) and aromatase inhibitor.

- Analysis of the current and future market competition in the global women's infertility therapeutics market. The key future market players covered are Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA and Merck.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the women's infertility market.

Reasons to buyThe report will enhance your decision making capability. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global women's infertility therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global women's infertility therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the global women's infertility therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Women's Infertility: Introduction 4

2.1 GlobalData Pipeline Report Guidance 4

3 Women's Infertility: Market Characterization 5

3.1 Women's Infertility Market Size 5

3.2 Women's Infertility Therapeutics Market Forecast and CAGR 6

3.3 Drivers and Barriers for the Women's Infertility Therapeutics Market 7

3.3.1 Drivers for the Women's Infertility therapeutics market 7

3.3.2 Barriers for the Women's Infertility therapeutics market 7

3.4 Opportunity and Unmet Need 7

3.5 Key Takeaway 8

4 Women's Infertility: Competitive Assessment 9

4.1 Overview 9

4.2 Strategic Competitor Assessment 9

4.3 Major Marketed Products for Women's Infertility 10

4.3.1 Clomid (clomiphene citrate) 10

4.3.2 Ovidrel (Choriogonadotropin Alfa) 10

4.3.3 GONAL-f (follitropin alfa) 11

4.3.4 Cetrotide (cetrorelix acetate) 12

4.4 Comparison of Major Marketed Products for Women's Infertility 14

4.5 Key Takeaway 14

5 Women's Infertility: Pipeline Assessment 15

5.1 Overview 15

5.2 Strategic Pipeline Assessment 15

5.2.1 Technology Trends Analytic Framework 15

5.3 Women's Infertility Therapeutics – Promising Drugs under Clinical Development 17

5.4 Molecule Profile for Promising Drugs under Clinical Development 17

5.4.1 ELONVA (corifollitropin alfa injection) 17

5.5 Women's Infertility Therapeutics – Clinical Pipeline by Mechanism of Action 18

5.6 Women's Infertility Therapeutics – Pipeline by Clinical Phases of Development 19

5.6.1 Women's Infertility Therapeutics – Phase III Clinical Pipeline 19

5.6.2 Women's Infertility Therapeutics – Phase II Clinical Pipeline 20

5.6.3 Women's Infertility Therapeutics – Phase I Clinical Pipeline 20

5.6.4 Women's Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline 20

5.7 Key Takeaway 20

6 Women's Infertility: Implications for Future Market Competition 21

7 Women's Infertility: Future Players in the Women's Infertility Market 22

7.1 Introduction 22

7.2 Merck & Co. 22

7.2.1 Company Overview 22

7.2.2 Financial Performance 22

7.2.3 Business Description 23

7.3 Dong-A Pharmaceuticals 24

7.3.1 Company Overview 24

7.4 Ferring Pharmaceuticals 25

7.4.1 Company Overview 25

7.5 PregLem SA 26

7.5.1 Company Overview 26

8 Women's Infertility: Appendix 27

8.1 Market Definitions 27

8.2 Scope of Pipeline Research 27

8.3 Abbreviations 27

8.4 Research Methodology 28

8.4.1 Coverage 28

8.4.2 Secondary Research 29

8.4.3 Forecasting 29

8.4.4 Primary Research 31

8.4.5 Expert Panel Validation 32

8.5 Contact Us 32

8.6 Disclaimer 32

8.7 Sources 32

1.1 List of TablesTable 1: Women's Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009 5

Table 2: Women's Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 6

Table 3: Comparison of Major Marketed Products for Women's Infertility, 2010 14

Table 4: Women's Infertility Therapeutics – Promising Drugs Under Clinical Development, 2010 17

Table 5: Women's Infertility Therapeutics – Phase III Clinical Pipeline, 2010 19

Table 6: Women's Infertility Therapeutics – Phase II Clinical Pipeline, 2010 20

Table 7: Women's Infertility Therapeutics – Phase I Clinical Pipeline, 2010 20

Table 8: Women's Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 20

Table 9: Merck & Co. – Women's Healthcare Pipeline Products, 2010 24

Table 10: Merck & Co. – Women's Infertility Pipeline Portfolio, 2010 24

Table 11: Dong-A Pharmaceutical Co., Ltd. – Women's Health Pipeline Portfolio, 2010 25

Table 12: Dong-A Pharmaceutical Co., Ltd. – Women's Infertility Pipeline Portfolio, 2010 25

Table 13: Ferring Pharmaceuticals – Women's Health Pipeline Portfolio, 2010 26

Table 14: Ferring Pharmaceuticals – Women's Infertility Pipeline Portfolio, 2010 26

Table 15: PregLem SA – Women's Health Pipeline Portfolio, 2010 26

Table 16: PregLem SA – Women's Infertility Pipeline Portfolio, 2010 26

1.2 List of FiguresFigure 1: Women's Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009 5

Figure 2: Women's Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 6

Figure 3: Opportunity and Unmet Need in the Women's Infertility Market, 2010 8

Figure 4: Strategic Competitor Assessment of the Marketed Products for Women's Infertility, 2010 9

Figure 5: Technology Trends Analytic Framework of Women's Infertility Pipeline, 2010 16

Figure 6: Technology Trends Analytic Framework of Women's Infertility Pipeline – Description, 2010 16

Figure 7: Women's Infertility Therapeutics– Clinical Pipeline by Mechanism Of Action, 2010 18

Figure 8: Women's Infertility Therapeutics Pipeline by Phase of Clinical Development, 2010 19

Figure 9: Women's Infertility – Implications for Future Market Competition, 2010 21

Figure 10: Women's Infertility Therapeutics Market – Clinical Pipeline by Company, 2010 22

Figure 11: GlobalData Methodology 28

Figure 12: GlobalData Market Forecasting Model 31

Companies mentioned Merck & Co.

Dong-A Pharmaceuticals

Ferring Pharmaceuticals

PregLem SA

To order this report:Pathology Industry: Women's Infertility - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
2. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
3. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
4. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
5. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
6. Reportlinker Adds Advances in Biopharmaceutical Technology in China
7. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
8. Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016
9. Reportlinker Adds Stem Cells Market And Applications. 2009-2015
10. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
11. Reportlinker Adds Global Nucleic Acid Testing Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 The ... and Brayton Cryocoolers), Service (Technical Support, Product Repairs & ... - Global Forecast to 2022", published by MarketsandMarkets, the ... Billion by 2022, at a CAGR of 7.29% between ... data Tables and 94 Figures spread through 159 Pages ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... hold an open house for regional manufacturers at its Maple Grove, Minnesota technical ... Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of tooling, ...
(Date:4/27/2016)... 2016 NanoStruck Technologies Inc. ... ( Frankfurt : 8NSK) gibt bekannt, ... 13. August 2015 die Genehmigung von der CNSX ... 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, um ... wurden 157.900.000 Einheiten mit dem ersten Teil der ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET ... Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and ... in small animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges ...
Breaking Biology Technology:
(Date:3/3/2016)... England and DE SOTO, Kansas ... , U.S.-based Stroke Detection Plus® to offer Oncimmune,s ... risk assessment and early detection of lung cancer ... large employers, unions and individuals. --> Early ... unions and individuals. --> Oncimmune, a leader ...
(Date:3/2/2016)... March 2, 2016 ... the "Global Biometrics as a Service ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ... Biometrics as a Service Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ...
(Date:3/1/2016)... , March 1, 2016  (RSAC Booth #3041) – ... a whopping $118 billion is lost to false positives, ... and inaccurate fraud detection. At the RSA Conference 2016, ... way companies handle authentication by devaluing the data fraudsters ... analytics. --> --> ...
Breaking Biology News(10 mins):